NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.So what: If you purchased Merck securities during the Class Period you ma ...

Core Viewpoint - Buying dividend stocks at a cheap valuation can be advantageous, especially if the underlying business remains strong despite a price decline, allowing investors to benefit from higher yields and potential price rebounds [1]. Group 1: PepsiCo - PepsiCo's shares are currently at their lowest price since 2021, with a low price-to-earnings (P/E) ratio observed only a few times in the past five years [3]. - The company has faced slowing growth rates and consumer pushback against price hikes, leading to decreased investor enthusiasm [4]. - In Q4 2024, PepsiCo's revenue was $27.8 billion, nearly flat compared to Q4 2023, but profits increased by 16% to over $1.5 billion. The stock has declined approximately 14% over the past year, with a current dividend yield of 3.6% [5]. Group 2: United Parcel Service (UPS) - UPS shares dropped over 16% following earnings release and a strategic shift away from reliance on Amazon, which will reduce Amazon delivery volumes to less than half by the second half of 2026 [6]. - CEO Carol Tome indicated that this strategy may enhance overall profitability despite lower revenue, focusing on better margins rather than just sales growth [7]. - UPS projects $89 billion in revenue for the current year, down from $91.1 billion in 2024, but the stock offers a high yield of 4.9%, significantly above the S&P 500 average of 1.2% [8]. Group 3: Merck - Merck's current dividend yield is 3.3%, with shares trading at their lowest since late 2022 [9]. - The company has paused shipments of its Gardasil vaccine to China due to weak demand, raising concerns about future sales amid potential trade tensions [10]. - There are worries about significant sales declines for Merck's top-selling cancer drug, Keytruda, as biosimilars may enter the market as early as 2028 [11]. - Despite current challenges, Merck's stock is trading at less than 10 times estimated future earnings, making it a potentially attractive long-term investment [12]. - Investors are advised to remain patient with Merck, as it continues to work on new product developments [13].

SAN DIEGO, Feb. 13, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, inclusive (the "Class Period"), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit.  Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck's top executives with violati ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools. GE Healthcare teamed up with AWS to build generative AI for medical use in 2024.  Now, a Thailand-based healthcare startup, HD, has built a marketplace, HDmall, to digitize the fragmented medical industry in Southeast Asia. The startup helps user ...

We’re a father-and-son team dedicated to helping individual investors achieve financial independence through strategic dividend investing. With years of combined experience and a deep understanding of the markets, we’ve developed a straightforward yet powerful method that empowers investors like you to take control of your financial future, create a massive dividend snowball, and retire happy and free. At The Dividend Freedom Tribe, we don’t serve institutional clients or cater to Wall Street’s elite. Inste ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its ...

INDIA - 2025/01/28: In this photo illustration, a Merck logo is seen displayed on a smartphone with ... [+] an Artificial Intelligence (text) in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates ...

This article might be the most instructive "case in point" about how I think as an investor. And hopefully it will reinforce or introduce to investors, as the case may be, why I am so adamant about what I call the "HOW" step of my investment process. ThatI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income invest ...

Shares of Merck (MRK -9.51%) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m. ET, but was down as much as 12.5% earlier in the day. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite gained 1.1% on the day.Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat Wall Street's revenue targets, weak guidance for 2025 disappointed investors.The numbersFor Q4 2024, Merck reported global sales of ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .I'm not breaking any news when I say that healthcare costs are becoming an issue. I believe we all have felt this through rising healthcare premiums and other ways.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, op ...